Tet2 deficiency–induced expansion of monocyte-derived macrophages promotes liver fibrosis
Journal of Experimental Medicine · 2026
DOI: 10.1084/jem.20251114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2026. Verfasst von Jiuxing Feng und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Shanghai Key Laboratory of Medical Epigenetics, Liver Cancer Institute, Institutes of Biomedical Sciences and Zhongshan Hospital, Fudan Universit…. Hauptthemen laut MEDLINE: Macrophages, Liver Cirrhosis, DNA-Binding Proteins, Proto-Oncogene Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation, Fudan University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Clonal hematopoiesis driven by Tet2 deficiency in myeloid cells (TetΔMye) is prevalent in elderly individuals; however, the role of Tet2ΔMye in liver fibrosis pathogenesis remains elusive. In this study, we demonstrated that Tet2-deficient monocyte-derived macrophages (MDMs) promoted cellular expansion and elevated C–C motif chemokine ligand 2/8 (Ccl2/8) secretion by stabilizing their mRNAs through 5hmC-mediated alterations in RNA–protein interactions. These chemokines engaged with the upregulated C–C motif chemokine receptor (Ccr2/3) on Tet2−/− monocytes, forming a positive feedback loop that amplified pro-inflammatory MDMs (pMDMs) accumulation in liver. Tet2−/− pMDMs activated hepatic stellate cells through IL-6, driving extracellular matrix deposition and fibrotic progression. Pharmacological inhibition of Ccl2/Ccl8 with Bindarit attenuated MDMs accumulation and liver fibrosis, whereas combined therapy with Bindarit and IL-6 neutralization synergistically suppressed liver fibrosis in Tet2ΔMye mice and aged chimeric models recapitulating Tet2ΔMye-related myeloid hematopoiesis. These findings present the mechanism that Tet2ΔMye aggravates liver fibrosis and highlight MDMs depletion plus IL-6 neutralization as a promising therapy for liver fibrosis in patients with Tet2ΔMye-related myeloid hematopoiesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Shanghai Key Laboratory of Medical Epigenetics, Liver Cancer Institute, Institutes of Biomedical Sciences and Zhongshan Hospital, Fudan University , Shanghai, P.R. China.
- East Hospital, Stem Cell Research Center, School of Medicine, Tongji University , Shanghai, P.R. China.
- Department of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
- Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Centre and Shanghai Key Laboratory of Medical Epigenetics, Fudan University , Shanghai, PR. China.
ORCID-Profile: Jiuxing Feng, Baitong Wu, Yu Li, Pengli Sun, Qian Liu, Qianxue Xiao, Jia-Bin Cai, Yimin Zheng, Haonan Chen, Yichi Xu, Yixin Liu, Guo-Ming Shi, Li Tan, Yujiang Geno Shi
Förderung
- China Postdoctoral Science Foundation
- Fudan University
- National Natural Science Foundation of China
Zitieren
APA
Feng, J., Wu, B., Li, Y., Sun, P., Liu, Q., Xiao, Q., Cai, J. B., Zheng, Y., Chen, H., Xu, Y., Liu, Y., Shi, G. M., Tan, L., & Shi, Y. G. (2026). Tet2 deficiency–induced expansion of monocyte-derived macrophages promotes liver fibrosis. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20251114
Vancouver
Feng J, Wu B, Li Y, Sun P, Liu Q, Xiao Q, et al. Tet2 deficiency–induced expansion of monocyte-derived macrophages promotes liver fibrosis. Journal of Experimental Medicine. 2026. doi:10.1084/jem.20251114
BibTeX
@article{Feng2026,
author = {Feng, Jiuxing and Wu, Baitong and Li, Yu and Sun, Pengli and Liu, Qian and Xiao, Qianxue and Cai, Jia-Bin and Zheng, Yimin and Chen, Haonan and Xu, Yichi and Liu, Yixin and Shi, Guo-Ming and Tan, Li and Shi, Yujiang Geno},
title = {Tet2 deficiency–induced expansion of monocyte-derived macrophages promotes liver fibrosis},
journal = {Journal of Experimental Medicine},
year = {2026},
doi = {10.1084/jem.20251114}
}
EUVIMED